Phase 3 Sclerosis Clinical Trials
65 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 65 trials
Recruiting
Phase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Multiple Sclerosis (MS) Primary Progressive
Zenas BioPharma (USA), LLC705 enrolled12 locationsNCT07067463
Recruiting
Phase 3
Evaluation of Efficacy and Safety of Rituximab and Mycophenolate Mofetil Combination in Patients With Interstitial Lung Disease Related to Systemic Sclerosis
Interstitial Lung Disease With Systemic Sclerosis
University Hospital, Tours102 enrolled1 locationNCT06549231
Recruiting
Phase 3
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)
Focal Segmental Glomerulosclerosis
Boehringer Ingelheim286 enrolled277 locationsNCT07220083
Recruiting
Phase 3
Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Amyotrophic Lateral Sclerosis
Prilenia500 enrolled16 locationsNCT07322003
Recruiting
Phase 3
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Secondary Progressive Multiple Sclerosis
Zenas BioPharma (USA), LLC990 enrolled12 locationsNCT07299019
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
Chronic Kidney DiseaseAtherosclerosis Cardiovascular Disease
Eli Lilly and Company7,140 enrolled568 locationsNCT07241390
Recruiting
Phase 2Phase 3
HEALEY ALS Platform Trial - Master Protocol
Amyotrophic Lateral Sclerosis
Merit E. Cudkowicz, MD1,500 enrolled81 locationsNCT04297683
Recruiting
Phase 3
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Secondary-progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals1,275 enrolled208 locationsNCT07225504
Recruiting
Phase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled106 locationsNCT06846281
Recruiting
Phase 3
Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis
Multiple Sclerosis
Sanofi160 enrolled32 locationsNCT07325292
Recruiting
Phase 3
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.800 enrolled47 locationsNCT05877963
Recruiting
Phase 3
Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)
Relapsing-remitting Multiple Sclerosis (RRMS)
Amgen444 enrolled109 locationsNCT06700343
Recruiting
Phase 3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
Systemic Sclerosis
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company92 enrolled55 locationsNCT07335562
Recruiting
Phase 3
Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Sandoz175 enrolled41 locationsNCT06847724
Recruiting
Phase 3
Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Bristol-Myers Squibb194 enrolled33 locationsNCT06408259
Recruiting
Phase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Sanofi1,600 enrolled384 locationsNCT06141473
Recruiting
Phase 3
Study of the Efficacy of Nintedanib+Tocilizumab in Patients With Systemic Sclerosis and Interstitial Lung Disease
Interstitial Lung DiseaseSystemic Sclerosis
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland86 enrolled1 locationNCT06297096
Recruiting
Phase 3
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
Relapsing Multiple Sclerosis
TG Therapeutics, Inc.360 enrolled42 locationsNCT07211633
Recruiting
Phase 2Phase 3
A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis
Focal segmental glomerulosclerosis (FSGS)Minimal Change Disease (MCD)
Bio-Thera Solutions192 enrolled1 locationNCT07499700
Recruiting
Phase 3
Effects of Ziltivekimab on Coronary Atherosclerotic Burden in Patients With Acute Myocardial Infarction
Coronary Artery DiseaseAcute Myocardial Infarction (AMI)Coronary Atherosclerosis of Native Coronary Artery
ECRI bv332 enrolled1 locationNCT07276282